BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Mecbotamab vedotin (CAB-AXL-ADC) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Mecbotamab vedotin (CAB-AXL-ADC)\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04918186-7653@assetmemo.bio
DTSTAMP:20261121T005926Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Mecbotamab vedotin (CAB-AXL-ADC): Phase 2 readout est. (NCT04918186
 )
DESCRIPTION:Mecbotamab vedotin (CAB-AXL-ADC)\, phase 2.\nStudy: Immunothera
 py Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer\n
 Estimated primary completion: 31 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/mecbotamab-vedotin-cab-axl-adc#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04918186
URL:https://assetmemo.bio/drug/mecbotamab-vedotin-cab-axl-adc#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
